Dossier AMM conditionnelle pour astrazenca

Type :

Date de publication : 19 octobre 2021

Résumé

COVID-19 Vaccine AstraZeneca

Product Information as approved by the CHMP on 29 January 2021, pending endorsement by the European Commission

Includes:

Package leaflet (for patients)
Summary of product characteristics (for healthcare professionals) Manufacturers and conditions of the marketing authorisation Labelling

Références & liens

https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf

Défilement vers le haut
Aller au contenu principal